MX2019012158A - Tratamiento para el asma con anticuerpo anti-tslp. - Google Patents

Tratamiento para el asma con anticuerpo anti-tslp.

Info

Publication number
MX2019012158A
MX2019012158A MX2019012158A MX2019012158A MX2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A
Authority
MX
Mexico
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
MX2019012158A
Other languages
English (en)
Spanish (es)
Inventor
R Parnes Jane
Griffiths Janet
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019012158A publication Critical patent/MX2019012158A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019012158A 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp. MX2019012158A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
MX2019012158A true MX2019012158A (es) 2019-12-16

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012158A MX2019012158A (es) 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp.

Country Status (21)

Country Link
US (3) US10828365B2 (OSRAM)
EP (1) EP3609917A1 (OSRAM)
JP (4) JP7330896B2 (OSRAM)
KR (2) KR20240070727A (OSRAM)
CN (1) CN110573525A (OSRAM)
AU (2) AU2018253118B2 (OSRAM)
BR (1) BR112019021482A2 (OSRAM)
CA (1) CA3059364A1 (OSRAM)
CL (1) CL2019002897A1 (OSRAM)
CO (1) CO2019011462A2 (OSRAM)
IL (1) IL269791B (OSRAM)
JO (1) JOP20190243A1 (OSRAM)
MX (1) MX2019012158A (OSRAM)
MY (1) MY207509A (OSRAM)
PE (1) PE20200484A1 (OSRAM)
PH (1) PH12019502331A1 (OSRAM)
SG (1) SG11201909322VA (OSRAM)
TN (1) TN2019000289A1 (OSRAM)
TW (2) TWI856945B (OSRAM)
UY (1) UY37676A (OSRAM)
WO (1) WO2018191479A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347377B1 (en) * 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
AU2020311432A1 (en) * 2019-07-11 2022-02-03 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
RS66646B1 (sr) * 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技(成都)有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
CN115279404A (zh) * 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
WO2021163588A1 (en) * 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
MX2023009971A (es) * 2021-03-03 2023-09-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composicion farmaceutica que contiene anticuerpo anti-tslp.
KR20230172508A (ko) * 2021-04-19 2023-12-22 메디뮨 리미티드 안정성이 개선된 항-tslp fab
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗il—13多特異性抗體構築體及其用途
TW202523697A (zh) * 2023-08-25 2025-06-16 美商普羅特歐拉吉克適美國公司 抗tslp抗體構築體及其用途
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
MX2017001531A (es) * 2014-08-08 2017-05-15 Alector Llc Anticuerpos anti-trem2 y metodos de uso de los mismos.
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Also Published As

Publication number Publication date
KR20190140956A (ko) 2019-12-20
TW201838652A (zh) 2018-11-01
JP2024150751A (ja) 2024-10-23
AU2018253118A1 (en) 2019-10-24
IL269791B (en) 2022-07-01
SG11201909322VA (en) 2019-11-28
CL2019002897A1 (es) 2020-03-06
TWI856945B (zh) 2024-10-01
CN110573525A (zh) 2019-12-13
KR102666879B1 (ko) 2024-05-23
KR20240070727A (ko) 2024-05-21
US10828365B2 (en) 2020-11-10
US20250032608A1 (en) 2025-01-30
US20210052726A1 (en) 2021-02-25
EP3609917A1 (en) 2020-02-19
CA3059364A1 (en) 2018-10-18
TW202523688A (zh) 2025-06-16
BR112019021482A2 (pt) 2020-05-12
AU2025204735A1 (en) 2025-07-17
PH12019502331A1 (en) 2020-09-28
CO2019011462A2 (es) 2019-10-31
AU2018253118B2 (en) 2025-04-10
TN2019000289A1 (en) 2021-05-07
JOP20190243A1 (ar) 2019-10-13
JP2023099233A (ja) 2023-07-11
IL269791A (en) 2019-11-28
PE20200484A1 (es) 2020-03-03
JP7330896B2 (ja) 2023-08-22
UY37676A (es) 2018-10-31
JP2025170430A (ja) 2025-11-18
US20180296669A1 (en) 2018-10-18
WO2018191479A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
JP2020516647A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
JOP20200309A1 (ar) أجسام مضادة لـ il-11
PH12018500482A1 (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
AU2017240801A8 (en) Chimeric receptors to FLT3 and methods of use thereof
MY205760A (en) Humanized antibodies against c-kit
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
CR20210010A (es) Anticuerpos dirigidos contra il-11ra
EA201791443A1 (ru) Естественные киллерные клетки и их применения
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
NZ746609A (en) Ilt7 binding molecules and methods of using the same
ZA202205936B (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
MY192390A (en) Method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof
MY201744A (en) Binding polypeptides and methods of making the same
WO2021011779A3 (en) Mesenchymal stem cell compositions
MX2025008918A (es) Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp
UA85646U (ru) Способ получение экстракта из эмбрионов кур